ENSAIOS EM RECRUTAMENTO NACIONAL

| RESERVED AREA | LANGUAGE

Lung Cancer Study Group

Ensaios Clínicos em recrutamento nacional Promovidos pela Indústria Farmacêutica

COAST
A phase 2 open-‐label, multicentre, randomized, multidrug plataforma study od Durvalumab alone or in combinationwith novel agentes in subjects with locally advanced, unresectable (stage III) NSCLC

NeoCOAST
A Phase 2 Open-‐label, Multicenter, Randomized, Multidrug Platform Study of Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Subjects With Resectable, Early-‐stage (I [> 2 cm] to IIIA) Non-‐small Cell Lung Cancer (NeoCOAST)

BO40336 (ALINA)
A Phase III, Open-‐Label, Randomized Study to Evaluate the Efficacy and Safety of adjuvante alectinib vs adjuvante Platinum-‐ Based Chemotherapy in Patients With Completely Resected Stage IB (Tumors Equal to or Larger Than 4cm) to Stage IIIA Anaplastic Lymphoma Kinase Positive Non-‐ Small Cell Lung Cancer

BCANOPY-‐A
Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-‐IIIA and IIIB (T>5cm N2) Completely Resected

CT-P16
A Double Blind, Randomized, Active Controlled, Parallel Group, Phase 3 Study to Compare Efficacy and Safety of CT- P16 and EU Approved Avastin as First Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer

BrainMets
Estudo Transversal para identificação da presença de metástases cerebrais ao diagnóstico, em doentes com carcinoma de pulmão de não pequenas células avançado e mutação do gene EGFR

NAVIGATE
A Phase 2 Basket Study of the Oral TRK Inhibitor Larotrectinib (LOXO-101) in Subjects With NTRK Fusion-positive Tumors

BI 13812
An Open Label, Phase I Dose-finding Study of BI 754111 in Combination With BI 754091 in Patients With Advanced Solid Cancers Followed by Expansion Cohorts at the Selected Dose of the Combination in Patients With Non-small Cell Lung Cancer and Other Solid Tumors

A Phase 1, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability Pharmacokinetics Immunogenicity, and Antitumor Activity of MEDI5752 in Subjects With Advanced Solid Tumors

©2020-25 Copyright GECP | All Rights Reserved | Contributors | Powered by JanelaWeb

error: ©GECP2025